Early Cancer Predictor Small team (2-10 employees) with a focused mission to develop a digital cancer progression predictor presents a niche solution ideal for strategic partnerships, pilot programs, and co-development deals with larger healthcare and diagnostics players seeking early risk stratification capabilities.

Straticyte Platform flagship product Straticyte positions Proteocyte AI in the early screening and risk assessment space for oral cancer, offering a clear entry point for collaborations with clinics, hospital systems, and payer-backed pilots aiming to reduce late-stage cancer incidence.

Strategic Advisory Recent additions of strategic and business advisors suggest an openness to partnerships, fundraising, and market strategy refinement, signaling readiness for channel partners, bioscience accelerators, and strategic investors seeking verified go-to-market plans.

Funding & Traction History of seed funding and a prior research collaboration with Medlior Health Outcomes Research Ltd. indicate credibility with funders and potential for grant-supported pilots, making it tangible for grant writers, public funding programs, and research collaborations.

Tech & Channels Technology stack includes modern web and analytics tools (WordPress, Shopify, Google Ads, Piwik PRO) suitable for rapid digital outreach, lead generation, and D2C or B2B outreach strategies, presenting opportunities for channel partners and co-marketing agreements with adjacent diagnostics players.